POSTN, periostin, 10631

N. diseases: 378; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.070 Biomarker disease BEFREE Twenty-four hub genes were confirmed, the survival analyses from the cBioPortal online platform revealed that topoisomerase (DNA) II α (TOP2A), periostin (POSTN), plasminogen activator, urokinase (PLAU), and versican (VCAN) may be involved in the carcinogenesis and progression of Pa, and the receiver-operating characteristic curves indicated their diagnostic value for Pa. 31297881 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.070 Biomarker disease BEFREE This study suggested that POSTN and CA242 are potential diagnostic serum biomarkers complementing CA19.9 in detecting early pancreatic cancer. 29945294 2018
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.070 Biomarker disease BEFREE Role of microenvironmental periostin in pancreatic cancer progression. 29163770 2017
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.070 Biomarker disease BEFREE Taken together, these findings suggest that POSTN promotes tumor angiogenesis via Erk/VEGF signaling in PaC and POSTN may be a new target for cancer anti-vascular treatment. 27223086 2016
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.070 Biomarker disease BEFREE Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. 27696296 2016
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.070 Biomarker disease BEFREE Ectopic expression of periostin was used to examine the effects of periostin on proliferation and invasiveness of pancreatic cancer cells in vitro. 21225237 2011
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.070 Biomarker disease BEFREE These findings suggest an important role of periostin in pancreatic cancer and provide a rationale to study periostin for diagnostic and therapeutic applications. 17043657 2007